Alfuzosin

Indications
 Oral
Benign prostatic hyperplasia
Adult: 2.5 mg tid. Max dose: 10 mg daily.
Elderly: Initially, 2.5 mg bid.
Renal impairment: Initiate with 2.5 mg bid. Adjust dose according to response.
Hepatic impairment: Mild-moderate impairment: Initiate with 2.5 mg daily, may increase to 2.5 mg bid gradually according to response. Modified-release preparations are not recommended.

Special Populations: Reduce dose in mild to moderate liver disease. Renal impairment: Start at 2.5 mg bid; adjust according to response.
Contraindications
 Severe hepatic impairment; history of postural hypotension and micturition syncope; intestinal occlusion; severe renal insufficiency; lactation.
Warnings / Precautions
 Elderly; hypertension; coronary insufficiency; angina (discontinue); renal or hepatic impairment. Monitor BP regularly. May affect ability to drive or operate machinery.
Adverse Reactions
 Drowsiness, postural hypotension, syncope, asthenia, depression, headache, dry mouth, GI disturbances, edema, blurred vision, rhinitis, erectile disorders, tachycardia, palpitation, hypersensitivity reactions; flushes; chest pain; dizziness; lack of energy.
Overdose Reactions
 May lead to hypotension. Maintain patient in supine position to restore BP. Otherwise, IV fluids and/or vasopressors may be needed. Monitor renal function.
Drug Interactions
 CYP3A4 inhibitors e.g. azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, telithromycin, and verapamil may increase the levels of alfuzosin. Reduced serum levels when used with CYP3A4 inducers e.g. aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin and rifamycins.
Potentially Fatal: Concurrent use with potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole or ritonavir) is contraindicated.
See Below for More alfuzosin Drug Interactions
Mechanism of Actions
 Alfuzosin is a quinazoline-derivative which exhibits selectivity for α1-adrenergic receptors in the lower urinary tract. Blockade of these adrenoreceptors causes relaxation of smooth muscle in the bladder neck and prostate, resulting in improvement in urine flow and a reduction in symptoms of benign prostatic hyperplasia.
Absorption: Readily absorbed after oral admin. Bioavaliability: about 64%.
Distribution: 90% bound to plasma proteins.
Metabolism: Extensively metabolised in the liver, mainly by the cytochrome P450 isoenzyme CYP3A4, to inactive metabolites.
Excretion: About 11% excreted unchanged in urine. Metabolites are mainly excreted in faeces via bile. Elimination half-life: about 3-5 hr.
Administration
 Should be taken with food. (Swallow whole. )
Extended-release: Should be taken with food. (Take immediately after the same meal each day. Swallow whole, do not chew/crush. )
Storage Conditions
 Oral: Store between 15-30°C.
ATC Classification
 G04CA01 - alfuzosin ; Belongs to the class of alpha-adrenoreceptor antagonists. Used in the treatment of benign prostatic hypertrophy.
Storage
 Oral: Store between 15-30°C.
Available As
  • Alfuzosin 10 mg

    • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Alfuzosin


    Alfuzosin Containing Brands

    We are Developing Our database, More results coming soon.

    Alfuzosin is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Alfuzosin

    We are Developing Our database, More results coming soon.